Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]
- Registry ID
- 2025-524131-39-00
- Source registry
- CTIS
- Status
- Authorised
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- Charite Universitaetsmedizin Berlin KöR
- Enrollment
- 112
- Last update
- 2026-08-13
Conditions
- Diseases [C] - Digestive System Diseases [C06]
- locally advanced or metastatic small bowel adenocarcinoma
Primary outcomes
Progression-free survival, defined as the time from the date of randomization to the date of first radiological disease progression according to RECIST 1.1 or the date of death from any cause. Date of the last contact known alive respectively date of the last tumor assessment known progression-free.
Locations
Related clinical trials
- A3921210 - OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
- J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
- A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn’s Disease
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
- A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis
View on source registry